A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. (Q44667134)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Marta Podda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Riccardo Haupt

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Alberto Garaventa

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Gianluca Severi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Stefano Mastrangelo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

7

Arcangelo Prete

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Simona Biasotti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Maria Rosa Pizzitola

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Elisabetta Viscardi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Bruno De Bernardi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

2488-2494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14635085%20AND%20SRC:MED&resulttype=core&format=json

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

DNA-topoisomerase I, a new target for the treatment of neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Incorporating toxicity considerations into the design of two-stage phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Phase II study of cisplatinum and carboplatinum (CACIS) combination in advanced stage neuroblastomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11797

7 January 2021